Elicio Therapeutics (ELTX) EBIT (2020 - 2026)

Elicio Therapeutics (ELTX) has reported EBIT for 7 consecutive years, with -$10.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBIT fell 3.35% year-over-year to -$10.4 million; the trailing twelve-month figure through Jun 2026 stood at -$37.9 million (up 15.07% YoY), and the FY2025 full-year result was -$37.7 million, up 16.17% from the prior year.
• EBIT improved to -$10.4 million in Q2 2026 per ELTX's latest filing, from -$10.6 million in the prior quarter.
• Across five years, EBIT topped out at -$5.8 million in Q3 2022 and bottomed at -$14.5 million in Q1 2022.
• Historically, EBIT has averaged -$9.6 million across 5 years, with a median of -$10.2 million in 2024.
• The widest YoY moves for EBIT: up 65.84% in 2022, down 140.73% in 2022.
• Over 5 years, EBIT stood at -$6.0 million in 2022, then tumbled by 57.56% to -$9.4 million in 2023, then tumbled by 43.48% to -$13.5 million in 2024, then jumped by 34.39% to -$8.8 million in 2025, then dropped by 17.95% to -$10.4 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered -$10.4 million, -$10.6 million, and -$8.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.